Filing Flows

Filing Flows › Biocryst Pharmaceuticals (BCRX) › Next earnings date

Biocryst Pharmaceuticals (BCRX) earnings: beat the estimate

Biocryst Pharmaceuticals (BCRX) reported on Nov 4, 2026 and beat the EPS estimate: $0.27 against $0.12 (+131.1%). Revenue was $180M for Q3 2026, +13% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+131.1% vs estimate
Beat rate100%

The last report

Biocryst Pharmaceuticals reported revenue of $180M for the third quarter 2026 (+13% Y/Y), net earnings $37.9M: Product $172M, License and other revenues $8.0M. How it makes money → · Every quarter →

Biocryst Pharmaceuticals: EPS against the estimate, last 5 reportsBiocryst Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported$0.07$0.16Nov 25$0.07$0.21Feb 26$0.11$0.14May 26$0.23$0.35Aug 26$0.12$0.27Nov 26
Latest (Nov 26): Estimate $0.12, Reported $0.27.

Biocryst Pharmaceuticals' latest quarter

Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.

Questions

Did Biocryst Pharmaceuticals beat earnings?

Biocryst Pharmaceuticals (BCRX) reported on Nov 4, 2026 and beat the EPS estimate: $0.27 against $0.12 (+131.1%).

When does BCRX report earnings?

The next date is not set yet.

Does Biocryst Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.